OPGN - オプジェン （OpGen Inc.）

OpGen has announced the expansion of its initial R&D agreement (signed in September 2022) with FIND, a global non-profit alliance for diagnostics, with potential revenue of €830k, roughly €130k hig…

Precision medicine company, OpGen (OPGN) signed an amendment to its research and development collaboration agreement with FIND, to expand the collaboration which was originally started…

Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md., April 05, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN , "OpGen" or "the Company")), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that it signed an amendment to its research and development ("R&D") collaboration agreement with FIND , to expand the collaboration which was originally started in fall of 2022. The work already completed under the collaboration will be expanded by three work packages increasing total project volume to up to € 830 thousand in revenue potential. The added deliverables will address the following topics: An Antimicrobial Stewardship Module supporting users with rule-based information to allow making the best treatment choices based on respective hospital''s drug availability; A "Data everywhere" concept, investigating hardware and software options for remote connectivity in the specific environments of low- and middle- income countries (LMICs); and Next Generation Sequencing ("NGS") strain analysis including isolates from several sub-Saharan African countries to investigate any potential sequence differences.

Parties add several deliverables to initial R&D collaboration contract Overall potential revenue increased to up to euro 830 thousand ROCKVILLE, Md. , April 05, 2023 (GLOBE NEWSWIRE) -- OpGen , Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of

OpGen''s FY22 update reflected a busy period for the company following the FY22 preliminary update in January 2023. Top-line performance continued to be affected by longer sales cycles, although the…

Gainers COMSovereign Holding Corp. (NASDAQ: COMS ) shares rose 58.4% to $0.1069 in pre-market trading after gaining more than 16% on Tuesday. Kalera Public Limited Company (NASDAQ: KAL ) rose 30% to $0.1183 in pre-market trading after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. OpGen, Inc. (NASDAQ: OPGN ) rose 19.2% to $0.23 in pre-market trading after declining around 10% on Tuesday. The company recently posted downbeat quarterly results. Cosmos Holdings Inc.. (NASDAQ: COSM ) rose 19.1% to $0.3899 in pre-market trading after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. Core Scientific, Inc. (NASDAQ: CORZ ) rose 18.9% to $0.1596 in pre-market trading after declining 20% on Tuesday. Golden Sun Education Group Limited (NASDAQ: GSUN ) rose 17.2% to $2.38 in pre-market trading. Venus Concept Inc. (NASDAQ: VERO ) shares rose 15.3% to $0.2522 in pre-market trading after climbing over 9% on Tuesday. Venus Concept recently announced completion of $6.72 million private placement financing.

OpGen Inc. (NASDAQ:OPGN) marked $0.19 per share on Thursday, up from a previous closing price of $0.18. While OpGen Inc. has overperformed by 4.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPGN fell by -89.12%, with highs and lows ranging from $1.76 to $0.16, whereas […]

OpGen, Inc. (NASDAQ:NASDAQ:OPGN) Q3 2022 Earnings Conference Call November 10, 2022 16:30 ET Company Participants Alyssa Factor - Investor Relations Associate, Edison Group Oliver Schacht -…

OpGen press release (OPGN): Q3 GAAP EPS of -$0.30 misses by $0.19.Revenue of $448.71M (+36086.3% Y/Y) beats by $447.41M.Cash and cash equivalents were approximately $10.3 million as…

ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

Gainers COMSovereign Holding Corp. (NASDAQ: COMS ) shares rose 58.4% to $0.1069 in pre-market trading after gaining more than 16% on Tuesday. Kalera Public Limited Company (NASDAQ: KAL ) rose 30% to $0.1183 in pre-market trading after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. OpGen, Inc. (NASDAQ: OPGN ) rose 19.2% to $0.23 in pre-market trading after declining around 10% on Tuesday. The company recently posted downbeat quarterly results. Cosmos Holdings Inc.. (NASDAQ: COSM ) rose 19.1% to $0.3899 in pre-market trading after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. Core Scientific, Inc. (NASDAQ: CORZ ) rose 18.9% to $0.1596 in pre-market trading after declining 20% on Tuesday. Golden Sun Education Group Limited (NASDAQ: GSUN ) rose 17.2% to $2.38 in pre-market trading. Venus Concept Inc. (NASDAQ: VERO ) shares rose 15.3% to $0.2522 in pre-market trading after climbing over 9% on Tuesday. Venus Concept recently announced completion of $6.72 million private placement financing.

OpGen Inc. (NASDAQ:OPGN) marked $0.19 per share on Thursday, up from a previous closing price of $0.18. While OpGen Inc. has overperformed by 4.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, OPGN fell by -89.12%, with highs and lows ranging from $1.76 to $0.16, whereas […]

OpGen, Inc. (NASDAQ:NASDAQ:OPGN) Q3 2022 Earnings Conference Call November 10, 2022 16:30 ET Company Participants Alyssa Factor - Investor Relations Associate, Edison Group Oliver Schacht -…

OpGen press release (OPGN): Q3 GAAP EPS of -$0.30 misses by $0.19.Revenue of $448.71M (+36086.3% Y/Y) beats by $447.41M.Cash and cash equivalents were approximately $10.3 million as…

ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.